SLGL.US Sol Gel Technologies Ltd

Healthcare Pharmaceuticals USA Stocks
52.83 USD
Close of Nov 17, 2026
34.10 97.97
Market cap
USD 173M
P/E
-
P/B
4.23x
ROE
-40.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SLGL.US undervalued?

Graham number

The Graham number of Sol Gel Technologies Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sol Gel Technologies Ltd fundamental analysis

No fundamental analysis for Sol Gel Technologies Ltd yet.

Sol Gel Technologies Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sol Gel Technologies Ltd

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in…

Full company profile